Introduction
============

Lung cancer is one of the most lethal diseases and has become the leading cause of cancer related deaths [@B1], [@B2]. Non-small cell lung cancer (NSCLC) is the largest subtype of lung cancer, comprising approximately 85% cases [@B3], [@B4]. The first-line treatment strategy for advanced NSCLC is based on the expression of oncogenic aberrations, such as epidermal growth factor receptor gene (*EGFR*), anaplastic lymphoma kinase gene (*ALK*), and orphan receptor tyrosine kinase (*ROS*) [@B1], [@B5]. However, most patients with NSCLC do not harbor these genetic aberrations; thus, cytotoxic chemotherapy is still the first-line treatment for such patients [@B6], [@B7]. Chemotherapy alone is associated with a median overall survival (OS) of 8 - 10 months, progression-free survival (PFS) of 4 - 6 months, and objective tumor response rates of 25 - 35% [@B8]. Moreover, the toxic effects of platinum-based chemotherapy are a concern for both clinicians and patients, as these severely impair quality of life [@B9]. Therefore, developing new agents with better effectiveness and less toxicity is crucial.

Drugs interrupting immune checkpoints, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed cell death protein 1 (PD-1), anti-programmed cell death-ligand 1 (PD-L1), and others, can enhance anti-tumor immunity and mediate durable cancer regressions [@B10], [@B11]. Previous studies have demonstrated promising therapeutic value of immune checkpoint inhibitors as these lead to improved tumor responses, prolonged long-term survival, and less toxicity for patients with metastatic NSCLC who had progressed during or after platinum-based chemotherapy [@B11]-[@B16]. However, patients with advanced NSCLC usually undergo rapid deterioration during the first course of treatment, and less than half of these patients receive second-line therapy [@B17].

Over time several studies exploring the safety and efficacy of immunotherapy as the first-line treatment strategy for advanced NSCLC have been published [@B18]-[@B32]. Due to the availability of a wide range of immunotherapeutic agents and distinct treatment strategies, there is no unanimous conclusion about the therapeutic status of immunotherapy in the management of naïve NSCLC patients. Thus, we performed this meta-analysis of randomized controlled clinical trials (RCTs), which included patients with locally advanced NSCLC with metastasis, to ascertain whether immune checkpoint agents alone or in combination with chemotherapy improve survival outcomes in NSCLC patients who received chemotherapy alone as a first-line treatment.

Material and methods
====================

Study selection
---------------

Electronic databases including Google Scholar, PMC, PubMed, EMBASE, Scopus, and the major conference proceedings (the American Society of Clinical Oncology and the European Society for Medical Oncology) were searched by two authors (Chen and Zhou) independently for RCTs published between 1^st^ January, 2010 and 1^st^ June, 2019. The following medical subject heading (MeSH) terms were used: (1) \"non-small cell lung cancer or NSCLC\"; (2) \"nivolumab or pembrolizumab or atezolizumab or ipilimumab or durvalumab\"; (3) \"PD-1 or PD-L1 or CTLA-4 or immune checkpoint inhibitor\"; (4) \"Randomized Controlled Trial or RCT\". All potentially eligible and relevant clinical studies were manually retrieved and examined. Studies that met the following criteria were included in this meta-analysis: (a) RCTs; (b) studies comparing the combination of immune therapy and chemotherapy with chemotherapy alone in the treatment of advanced treatment-naive NSCLC patients; and (c) studies comparing immune therapy alone with chemotherapy alone in the treatment of advanced treatment-naive NSCLC patients. Non-randomized controlled trials, or studies unrelated to the first-line immune therapy, were excluded. Ultimately, 14 RCTs were included for quantitative analysis (Fig. [1](#F1){ref-type="fig"}). Any disagreements about the processes of study selection, data extraction, and methodological quality assessment were resolved by discussion and consensus with an independent expert (Zhuang).

Data Extraction
---------------

The following information from the eligible studies were extracted by two authors (Tang and Chen) independently: year of publication, number of included patients, treatment regimen, and clinical outcomes. Clinical outcome measures included tumor response, long-term survival \[progression-free survival (PFS) and overall survival (OS)\], and the toxicity (3-5 grade toxicity and toxicity leading to discontinuation of treatment). Tumor response was stratified as objective responders who obtained a complete or partial response and as non-responders who experienced a stable or progressive disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [@B33].

Assessment of methodological quality
------------------------------------

Two authors (Chen and Zhou) independently assessed the methodological quality of the eligible studies according to the Cochrane Collaboration guidelines v5.1.0 [@B34].

Data analysis
-------------

All statistical analyses were performed using Stata12.0 software (Stata Corporation, College Station, TX, USA). Risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated for dichotomous data. Heterogeneity among these included studies was evaluated using I^2^ statistics, where an I^2^ value \> 50% was defined as substantial heterogeneity according to the Cochrane Collaboration guidelines v5.1.0 [@B34]. When I^2^ was \< 50%, the fixed-effects model was used to assess outcomes; otherwise, the random-effects model were preferred. Sensitivity analysis using both fixed and random-effect models for the same data was conducted to confirm the robustness and reliability of the results.

Results
=======

1.1. Search strategy {#Section1.1}
--------------------

The database search retrieved 5220 records. After deleting duplicate results, a total of 3410 abstracts were screened for eligibility, and 42 clinical trials were considered potentially eligible for inclusion based on titles and abstract review. After retrieving and further analyzing the full-text of these studies, another 28 studies were excluded; the remaining 14 studies [@B18]-[@B32] were finally included in the meta-analysis (Fig. [1](#F1){ref-type="fig"}). These 14 RCTs included a total of 8,081 patients: 4,391 patients had been administered immunotherapy alone or combination of chemotherapy and immunotherapy, and the remaining the 3,690 patients had been administered platinum-based chemotherapy alone. The characteristics of all 14 included studies are shown in Table [1](#T1){ref-type="table"}. Among these 14 included studies, ten RCTs had compared combination of checkpoint inhibitor and chemotherapy with chemotherapy alone [@B18]-[@B26], [@B31], [@B32]. The other four RCTs had compared checkpoint inhibitor alone with chemotherapy alone [@B27]-[@B30].

1.2. Outcome assessments {#Section1.2}
------------------------

### 1.2.1 Tumor response {#Section1.2.1}

The results based on ten RCTs [@B18]-[@B26], [@B31], [@B32] showed that combined immunotherapy and chemotherapy had significant benefit compared to chemotherapy alone with respect to tumor response (RR, 1.27; 95% CI, 1.09 to 1.48; I^2^ = 66.8%) (Fig. [2](#F2){ref-type="fig"}). Additionally, the immune-checkpoint inhibitor alone was not inferior to chemotherapy alone as the first-line therapy with respect to tumor response rate (RR, 1.13; 95% CI, 0.88 to 1.46; I^2^ = 67.9%) [@B27]-[@B30] (Fig. [2](#F2){ref-type="fig"}). As a whole, the use of the immunotherapy as the first-line therapy increased the objective tumor response (RR, 1.22; 95% CI, 1.08 to 1.39; I^2^ = 65.7%) (Fig. [2](#F2){ref-type="fig"}).

1.3. Toxicity {#Section1.3}
-------------

The pooled results showed that the combination of immunotherapy and chemotherapy significantly increased toxicity compared to chemotherapy alone (RR, 1.11; 95% CI, 1.04 to 1.18; I^2^ = 7.2%) [@B18]-[@B26], [@B31], [@B32]. However, no significant difference in 3 - 5 grade toxicity was found between patients in the monotherapy arms (RR, 0.69; 95% CI, 0.40 to 1.19; I^2^ = 94.2%) (Fig. [3](#F3){ref-type="fig"}A) [@B27]-[@B30]. Furthermore, more patients who underwent the combination of immunotherapy and chemotherapy discontinued their treatment due to the toxicity in combination of immunotherapy and chemotherapy group compared to chemotherapy alone (RR, 1.46; 95% CI, 1.23 to 1.74; I^2^ = 0%) [@B18], [@B19], [@B21]-[@B23], [@B31], [@B32]. However, patients who discontinued their treatment due to toxicity was comparable between groups of immune therapy alone and chemotherapy alone (RR, 1.26; 95% CI, 0.78 to 2.04; I^2^ = 70.5%) (Fig. [3](#F3){ref-type="fig"}B) [@B27]-[@B30].

1.4. Progression-free survival and overall survival {#Section1.4}
---------------------------------------------------

Based on random effects model analysis, a statistically significant benefit of combination of immune therapy and chemotherapy over chemotherapy alone was observed in term of PFS (HR, -0.43; 95% CI, -0.56 to -0.31; I^2^ = 72.6%) (Fig. [4](#F4){ref-type="fig"}A) [@B18]-[@B26], [@B31], [@B32]. The OS also improved upon addition of an immune checkpoint inhibitor with chemotherapy as the first-line therapy (HR, -0.30; 95% CI, -0.45 to -0.14; I^2^ = 72.2%) (Fig. [4](#F4){ref-type="fig"}B). However, there was no significant difference between patients who received immunotherapy compared to those who took platinum-based chemotherapy in terms of PFS (HR, -0.24; 95% CI, -0.61 to 0.14, I^2^ = 90.4%; Fig. [4](#F4){ref-type="fig"}A) and OS (HR, -0.20; 95% CI, -0.43 to 0.03; I^2^ = 64.2%; Fig. [4](#F4){ref-type="fig"}B) [@B27]-[@B30].

Furthermore, the subgroup analysis of patients with PD-L1 expression less than 1% revealed that both the PFS and OS were prolonged in the combination of immune therapy and chemotherapy compared with chemotherapy alone (HR, -0.33; 95% CI, -0.45 to -0.22; I^2^ = 36.2% (Fig [5](#F5){ref-type="fig"}A) and HR, -0.27; 95% CI, -0.44 to -0.10; I^2^ = 0.0% (Fig [5](#F5){ref-type="fig"}B)).

1.5. Methodological quality and sensitivity analyses {#Section1.5}
----------------------------------------------------

The methodological quality of the eligible studies is shown in Figure [6](#F6){ref-type="fig"}. All studies were assessed as level A. The sensitivity analyses showed robustness and reliability of our results.

Discussion
==========

Our meta-analysis aimed to compare the treatment regimes of immunotherapy alone or in combination with chemotherapy with chemotherapy alone in patients with advanced treatment-naive NSCLC.

Based on all the available information extracted from the included trials, we found that combination of immunotherapy and platinum-based chemotherapy as a first-line therapy has a favorable long-term effect. It is important to note that the studies, which compared the combination of chemotherapy and immunotherapy with chemotherapy alone, included all treatment-naive patients regardless of PD-L1 expression on tumor cells. Due to the functional mechanism of the immune checkpoint inhibitor, expression levels of PD-L1 on tumor cells assessed by immunohistochemistry have been regarded as a potential responsive biomarker to these agents [@B14], [@B35]. The previous study showed that the treatment efficiency in patients with a higher PD-L1 tumor-expression level was significantly better than those with a lower PD-L1 tumor-expression level, when treated by the immune checkpoints inhibitor [@B36], [@B37]. But, the subgroup analysis of this study showed that patients who had low or negative expression of PD-L1(≤1%) also benefitted from combined immunotherapy and chemotherapy as a first-line treatment in both PFS and OS. Although favorable long-term survival was observed in combined immunotherapy and chemotherapy group, the initial 3-6 month survival curve often overlaps or even crosses [@B38], which means that the efficacy of immunotherapy combined with chemotherapy in the early stage of treatment may not be superior to chemotherapy[@B18]-[@B26]. The higher rate of toxicity might offset the therapeutic effect of the combination of immunotherapy and chemotherapy at the onset of treatment [@B38].

Comparison of monotherapy arms of immune-checkpoint inhibitors and chemotherapy shows that selected patients with positive PD-L1 tumors [@B27], [@B29], [@B30] or a high mutation burden [@B28], who were administered immunotherapy alone, experienced longer PFS and OS. However, the difference was not significant with high heterogeneity among the studies. The results of the KEYNOTE-024 study demonstrated an advantage of pembrolizumab over chemotherapy in patients with a PD-L1 tumor-expression level ≥50% with regards to long-term survival. PFS improvement of 4.3 months was observed in the pembrolizumab group, despite the finding that 43% of patients who had undergone chemotherapy crossed over to the pembrolizumab group [@B29]. The results of KEYNOTE-042 [@B30] which recruited treatment-naïve stage IIIB-IV NSCLC patients with a PD-L1 tumor-expression level ≥1% demonstrated patients in the pembrolizumab group enduring a prolonged OS compared with chemotherapy group. The subgroup analysis of patients with a PD-L1 tumor-expression level ≥ 50% showed that the PFS and OS were significantly longer in pembrolizumab group compared with chemotherapy group. However, in patients with a PD-L1 tumor-expression level \<50%, there was no significant difference in PFS and OS between the two groups [@B30]. Based on these observations, we proposed that pembrolizumab alone is effective in patients a PD-L1 tumor-expression level ≥50%. However, in the CheckMate 026 study, no significant advantage of nivolumab over chemotherapy was observed in terms of objective tumor response and long-term survival among patients with PD-L1 expression \>5% [@B27]. The subgroup analysis demonstrated that even in patients with PD-L1 expression \>50%, there is no significant difference between nivolumab monotherapy group and chemotherapy group. Positive detection of PD-L1 on tumor cells alone may not be sufficient to predict outcomes among patients who receive immunotherapy. Owing to the complexity of the immune system, patients with low- PD-L-1 expression may also benefit from immunotherapy. Thus, new biomarkers, such as tumor mutational burden for response to immune-oncological agent, beyond PD-L1 expression levels, may be the most critical markers for selecting patients for immunotherapy. The CheckMate 026 trial demonstrated that among patients with a high tumor-mutation burden, nivolumab monotherapy achieved a higher response rate compared to chemotherapy alone (47% *vs*. 28%). The median PFS of patients receiving nivolumab monotherapy (9.7 months) has been reported to be much longer than those receiving chemotherapy alone (5.8 months) [@B27]. Furthermore, the CheckMate 227 trial demonstrated that PFS was significantly longer with first-line nivolumab plus ipilimumab (7.2 months) compared to chemotherapy (5.5 months) among NSCLC patients with a high tumor mutational burden (≥10 mutations per megabase), irrespective of PD-L1 expression levels.

Numerous limitations of these trials may hinder the fairness of this meta-analysis. Since only 14 RCTs were included in this meta-analysis, the results were underpowered. Furthermore, the HRs and corresponding 95% CIs were mainly extracted from the original studies without access to individualized data, which might have contributed to reporting bias. High heterogeneity was observed among the included studies, which may have decreased the strength of our meta-analysis. The high heterogeneity may be explained by the following: First, different immune checkpoint inhibitor regimens were used in different studies. Second, inclusion criteria differed among the included studies. Third, different treatment strategies had been used among studies.

The results of this meta-analysis demonstrated the superiority of combined immunotherapy with chemotherapy over chemotherapy alone in terms of tumor response and long-term survival as a first-line treatment strategy for advanced NSCLC patients but with higher rate of 3 - 5 grade toxicity. And immune-checkpoint inhibitors alone showed similar tumor response, toxicity and long-term outcomes compared to platinum-based chemotherapy in selected patients.
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###### 

Summary of 14 randomized controlled trials included in the meta-analysis.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study           Author                              Year   Study Group\               Control Group\             Inclusion criteria         
                                                             (regime and no. of Pts.)   (regime and no. of Pts.)                              
  --------------- ----------------------------------- ------ -------------------------- -------------------------- -------------------- ----- -------------------------------------------------------------------------------------------------------------------------------------
  CA184-041       Lynch et al. [@B25]                 2012   Ipi+Chemo                  70                         Chemo alone          66    Stage IIIB or IV NSCLC

  KEYNOTE 021     Langer et al. [@B19]                2016   Pembro+Chemo               60                         Chemo alone          63    Stage IIIB or IV, non-squamous NSCLC without targetable genetic aberration

  NCT01285609     Govindan et al. [@B26]              2017   Ipi+Chemo                  388                        Chemo alone          361   stage IV or recurrent squamous NSCLC

  IMpower 150     Socinski et al. [@B20]              2018   Atezo+Chemo                400                        Chemo alone          400   Stage IIIB or IV, non-squamous NSCLC without targetable genetic aberration

  IMpower 131     Jotte et al. [@B22]                 2018   Atezo+Chemo                343                        Chemo alone          340   Stage IV, squamous NSCLC without

  IMpower 132     Papadimitrakopoulou et al. [@B23]   2018   Atezo+Chemo                292                        Chemo alone          286   Stage IV non-squamous NSCLC without targetable genetic aberration

  KEYNOTE 407     Paz-Ares et al. [@B21]              2018   Pembro+Chemo               278                        Chemo alone          281   Stage IV, squamous NSCLC

  KEYNOTE 189     Gandhi et al. [@B18]                2018   Pembro+Chemo               410                        Chemo alone          206   Stage IV non-squamous NSCLC without targetable genetic aberration

  IMpower 130     West et al. [@B24]                  2019   Atezo+Chemo                473                        Chemo alone          232   Stage IV, non-squamous NSCLC without targetable genetic aberration

  PACIFIC         Antonia et al. [@B31], [@B32]       2018   Durva+Chemo                476                        Chemo alone          237   stage III, unresectable NSCLC

  KEYNOTE 024     Reck et al. [@B29]                  2016   Pembro alone               154                        Chemo alone          151   Stage IIIB or IV, NSCLC without targetable genetic aberration but with a PD-L1 tumor-expression level of 50% or more

  CheckMate 026   Carbone et al. [@B27]               2017   Nivo alone                 271                        Chemo alone          270   Stage IV or recurrent NSCLC without targetable genetic aberration but with a PD-L1 tumor-expression level of 5% or more

  CheckMate 227   Hellmann et al. [@B28]              2018   Nivo+Ipi                   139                        Chemo alone          160   Stage IV or recurrent NSCLC without targetable genetic aberration, with a high tumor mutational burden (≥10 mutations per megabase)

  KEYNOTE 042     Mok et al. [@B30]                   2018   Pembro alone               637                        Chemo alone          637   Stage IV or recurrent NSCLC without targetable genetic aberration but with a PD-L1 tumor-expression level of 1% or more
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** *Pts* -patients, *Pembro-* Pembrolizumab, *Atezo* -Atezolizumab, *Nivo-* Nivolumab, *Ipi-* Ipilimumab, *Durva*-Durvalumab, *Chemo-* Chemotherapy
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